Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OMEROS CORPORATION

(OMER)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Omeros: Q2 Earnings Snapshot

08/09/2021 | 04:26pm EDT

SEATTLE (AP) _ Omeros Corporation (OMER) on Monday reported a loss of $28.6 million in its second quarter.

The Seattle-based company said it had a loss of 46 cents per share. Losses, adjusted for non-recurring costs, came to 40 cents per share.

The drug developer posted revenue of $28.8 million in the period.

Omeros shares have climbed roughly 2% since the beginning of the year. In the final minutes of trading on Monday, shares hit $14.53, an increase of roughly 3% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on OMER at https://www.zacks.com/ap/OMER

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about OMEROS CORPORATION
10/19OMEROS : HC Wainwright Adjusts Price Target on Omeros to $12 From $19, Maintains Buy Ratin..
MT
10/18Top Midday Decliners
MT
10/18Omeros Shares Tumble as FDA Turns Away Narsoplimab Application
DJ
10/18Top Premarket Decliners
MT
10/18OMEROS : Receives Complete Response Letter from FDA for Biologics License Application for ..
PU
10/18OMEROS : Says FDA Requires Additional Information on Stem Cell Transplant Therapy Narsopli..
MT
10/18OMEROS CORP : Change in Directors or Principal Officers, Regulation FD Disclosure, Other E..
AQ
10/18Omeros Corporation Announces Retirement of Ray Aspiri from the Board of Directors
CI
10/18OMEROS : Receives Complete Response Letter from FDA for Biologics License Application for ..
BU
10/18Omeros Receives Complete Response Letter from FDA for Biologics License Application for..
CI
More news
Analyst Recommendations on OMEROS CORPORATION
More recommendations
Financials (USD)
Sales 2021 108 M - -
Net income 2021 -124 M - -
Net Debt 2021 334 M - -
P/E ratio 2021 -3,37x
Yield 2021 -
Capitalization 406 M 406 M -
EV / Sales 2021 6,84x
EV / Sales 2022 4,96x
Nbr of Employees 277
Free-Float 95,9%
Chart OMEROS CORPORATION
Duration : Period :
Omeros Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OMEROS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 6,49 $
Average target price 18,75 $
Spread / Average Target 189%
EPS Revisions
Managers and Directors
Gregory A. Demopulos Chairman, President & Chief Executive Officer
Michael A. Jacobsen Chief Financial Officer, Treasurer & VP
George A. Gaitanaris Chief Scientific Officer & Vice President-Science
J. Steven Whitaker Chief Medical Officer & Vice President
Thomas J. Cable Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OMEROS CORPORATION-54.57%406
CSL LIMITED4.48%100 729
WUXI BIOLOGICS (CAYMAN) INC.10.21%61 841
SAMSUNG BIOLOGICS CO.,LTD.6.54%49 427
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.8.14%39 464